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Abstract To delineate the functional significance of IL-
17 Receptor (IL-17RA) and characterize the IL-17 pro-
ducing T cell (Th17) subpopulation in psoriatic arthritis
(PsA). Mononuclear cells from blood and synovial fluid
(SF) were obtained from PsA (n = 20), rheumatoid
arthritis (RA, n = 20) and osteoarthritis (OA, n = 20)
patients. Synoviocytes (FLS) were isolated from the syn-
ovium of RA (n = 5), PsA (n = 5) and OA (n = 5)
patients. IL-17RA expression in FLS was identified by
western blotting (WB) and flowcytometry. T lymphocytes
derived from the SF of these patients were studied to
identify and phenotype the Th17 cells. The functional
significance of IL-17RA was determined by evaluating its
regulatory role on the production of proinflammatory
cytokines and endopeptidase. IL-17RA expression was
found to be significantly higher in FLS of RA
(15.7% ± 4.9) and PsA (4.5% ± 0.9) in comparison to OA
(1.14% ± 0.9). Western blot analyses showed that the
relative intensity (RI) of IL-17RA protein was higher in
RA and PsA compared to OA (Fisher exact, P \ 0.01). A
significant enrichment of IL-17-producing CD4? T cells
(7.9% ± 2.8) was observed in the SF of PsA patients
compared to that of OA patients (P \ .001). Compared to
OA-FLS, recombinant IL-17 induced higher levels of IL-6,
IL-8, and MMP-3 production in PsA-FLS. Blockage of
IL-17RA with an anti-IL-17RA antibody inhibited the
production of IL-6, IL-8, and MMP-3. This is the first
report to demonstrate the functional significance of IL-
17RA in PsA. Results of this study support the hypothesis
that IL-17RA blocking antibodies have the potential to be a
therapeutic option for psoriatic arthritis.
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Abbreviations
IL-17 Interleukin 17
IL-17R IL-17 receptor
Th17 IL-17 producing T helper cells
IFN-c Interferon-c
FLS Fibroblast like synovial cells
MMP-3 Matrix metalloproteinase-3
OA Osteoarthritis
PBMC Peripheral blood mononuclear cells
PsA Psoriatic arthritis
RORct Retinoic acid–related orphan receptor ct
SFMC Synovial fluid derived mononuclear cells
TGFb Transforming growth factor beta
Introduction
T-helper 17 (Th17) cells are a unique effector CD4? T-cell
subset characterized by their production of interleukin
(IL)-17[1–4]. The binding of IL-17 to an IL-17 receptor
expressed on epithelial, endothelial, or fibroblastic stromal
cells induces significant events in many tissues. Through
the ubiquitously expressed IL-17 receptor, IL-17 induces
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the secretion of proinflammatory cytokines [5, 6], recruits
neutrophils/monocytes and triggers an immune mediated
inflammatory reaction [7, 8]. IL-17 also stimulates osteo-
clast formation and bone resorption [9]. Aberrant Th17 cell
responses have been linked to various murine autoimmune
diseases, including collagen-induced arthritis, autoimmune
encephalomyelitis, and primary biliary cirrhosis [10–12].
Recent studies also indicate that Th17 cells have a critical
role in the pathogenesis of several human autoimmune
diseases, such as rheumatoid arthritis, juvenile idiopathic
arthritis, and psoriasis [4, 7, 10, 13, 14].
Psoriasis is a chronic inflammatory disease of the skin. In
addition to the cutaneous system, it often involves the
musculoskeletal system and occasionally the gastrointesti-
nal tract and eye. Therefore, it is often referred to as psoriatic
disease, to encompass the varied involvement of diseased
tissues and organs [15]. The role of Th17 in the pathogenesis
of psoriasis is currently under investigation. IL-17A is ele-
vated in psoriatic lesions and induces IL-6, IL-8, ICAM-I,
and MHC II expression in keratinocytes [14, 16–18]; these
biological features are characteristic of keratinocytes in
lesional psoriasis. Very limited information is available on
the role of IL-17 in psoriatic arthritis and there are no studies
available about the distribution and functional significance
of IL-17 R in psoriatic arthritis (PsA).
In this study, in order to determine the role of IL-17R in
the pathogenesis of PsA and to explore IL-17R as a target
therapeutic molecule for PsA following studies were per-
formed: (i) IL-17RA expression was analyzed in synovio-
cytes (FLS) obtained from synovial tissues of patients with
PsA and compared it with FLS from rheumatoid arthritis
(RA) and osteoarthritis (OA) patients, (ii) Th17 cells were
identified in synovial fluid from PsA patients and their
phenotypes and functional significance were determined,
(iii) the functional significance of IL-17R was investigated
in FLS derived from PsA, and (iv) the regulatory role of IL-
17/IL-17RA system was further substantiated by evaluating
whether a monoclonal antibody against IL-17RA (anti-
human IL-17RA mAb, M202, Amgen, Thousand Oaks, CA
[19]) inhibits IL-17-induced proinflammatory cytokine and
metalloproteinase production.
Materials and methods
Study population
This study was approved by the Institutional Review Board
of Stanford University and VAMC Sacramento. Specimens
were collected from patients with active PsA, OA and RA,
and healthy controls. OA and RA patients were recruited
according to the clinical, laboratory, and radiographic
classification criteria of the American College of
Rheumatology. Psoriatic arthritis patients had either olig-
oarthritis or symmetric polyarthritis as described by Moll
and Wright [20]. All PsA patients fulfilled the CASPAR
classification criteria for PsA. Patients had a complete
physical examination, evaluation of severity of psoriasis
and arthritis, appropriate blood tests and radiological
studies. Synovial fluid (SF) and synovial tissues were
collected from PsA, RA and OA patients with active
arthritis of one or both knees. The inclusion criteria for RA
and PsA utilized by this study were designed to limit
participants to only those with the active disease. Active
RA and PsA were defined by the presence of at least three
swollen and three tender joints. In addition, for PsA the
presence of plaque psoriasis with a qualifying lesion at
least 2 cm in diameter was required. Body surface area
(BSA) affected by psoriatic skin involvement was mea-
sured. Patients were evaluated for the swollen joint count,
the tender joint count, patient’s assessment of pain, ESR
and CRP. We tried to enroll patients who have not taken
DMARDs (methotrexate, leflunomide, cyclosporine,
hydroxychloroquine, sulfasalazine, azathioprime) and bio-
logic agents within last 3 months. Types of specimens,
number of subjects, disease type and use of DMARDs for
specific experiments are described in appropriate sections.
Various assays were done on patient samples, as described
under specific subheadings in the following sections.
Peripheral blood mononuclear cells (PBMC) and syno-
vial fluid mononuclear cells (SFMC) were obtained from
PsA (n = 20), RA (n = 20), and OA (n = 20) patients.
Paired samples of PBMC and SFMC were obtained. All
arthritis patients had active disease; they required thera-
peutic joint aspiration and/or intra-articular injection of
steroids. 4 mm size punch biopsies were collected from
psoriasis plaques (n = 25) and non-lesional psoriatic skin
(n = 15). Biopsies of normal skin were used as controls
(n = 15) from our tissue bank. Synovial tissues were
studied from PsA (n = 5), RA (n = 5), OA (n = 5) and
normal subjects with meniscal tear (n = 5). These subjects
required an arthroscopic procedure or joint replacement.
Identification of IL-17 receptor and its functional
significance
Isolation of FLS from synovial tissue
Synoviocytes/Fibroblast like synovial cells (FLS) were
isolated from synovial tissue biopsies of healthy subjects
with meniscal tears (n = 4), RA (n = 5), PsA (n = 5), and
OA (n = 5). Synoviocyte cell suspensions were prepared
from synovial tissues as described by Valencia et al. [21]
and FLS were isolated in accordance with our standard-
ized protocols [21–23]. After the third passage, cells
appeared fibroblast-like and were negative with anti-CD68
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monoclonal antibody, suggesting they were composed
mainly of FLS. Cells were maintained at 37C in a
humidified atmosphere of 95% air and 5% CO2 and cul-
tured in complete medium (DMEM with sodium pyruvate,
penicillin, streptomycin, 10% fetal bovine serum). All FLS
were positive for the fibroblast-specific markers ASO2 and
CD55. No expression of the macrophage-specific marker
CD68, or pan endothelial cell adhesion molecule (PECAM)
CD31 could be detected in FLS cultures, thus excluding
possible contamination from synovial fibroblasts by syno-
vial macrophages and endothelial cells. All experiments
were performed with cells between the third and fifth
passages.
IL-17RA expression on FLS by flowcytometry
Adherent FLS were detached by accutase (PAA, Linz,
Austria), washed with PBS and incubated with the mouse
anti-human IL-17RA monoclonal antibody, M202 (20 ng/
ml, Amgen USA), at 4C for 20 min. Cells were then
washed with phosphate buffered saline (PBS) containing
2% fetal bovine serum and were incubated with goat anti-
mouse IgG-FITC (BD-Pharmingen, San Diego, CA) for
20 min at 4C. The cells were washed and fixed with 0.5%
paraformaldehyde for FACS analysis. At least 100,000
cells were collected in FACSAria (BD Biosciences, San
Jose, CA). Data were analyzed using FlowJo software
(Treestar, Ashland, OR).
Western blot analysis of IL-17RA
FLS were washed twice with ice cold PBS. Cells were
harvested by scraping into ice-cold RIPA buffer (PBS, 1%
Nonidet P-40, 0.5% sodium deoxycholate). Inhibitors were
added in the following concentrations: 1 mM PMSF, 1 mg/
ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM
Na3VO4 and 1 mM NaF (Sigma). The cell lysate was
incubated at 4C for 60 min and centrifuged at 14000 rpm
for 20 min at 4C; the supernatant was then collected.
Protein concentration in the supernatant was quantified
using the BCA Protein Assay Reagent Kit (Thermo-Fisher
scientific, USA) and 30 lg of cell lysate protein was used
for western blot analysis. Proteins were electroblotted from
NuPAGE gels (NOVEX, Frankfurt-Hoechst, Germany)
onto a Hybond ECL membrane (Amersham, Freiburg,
Germany). The membrane was blocked with 1% BSA in
TBST for 1 h at room temperature. Blots were incubated
with the primary antibody IL-17R mAb (Amgen, USA) at
1:250 dilution; a-tubulin, (Cell signaling Technologies),
1:250 dilution in TBST with 1% BSA at room temperature
for 2 h. Blots were washed three times and then incubated
for 1 h with 1:20000 dilution of goat anti-mouse IgG
secondary antibody coupled with horseradish peroxidase
(Dianova, Hamburg, Germany). Immunodetection was
accomplished using the ECL western blotting detection
reagents (Thermo-Fisher Scientific, USA) for chemilumi-
nescent detection. Immunoreactivity was quantified by
scanning densitometry using Image J software (NIH,
Bethesda, MD, USA).
Inhibitory effect of IL-17RA mAb, M202, on IL-6, IL-8,
and MMP3 production by IL-17-stimulated FLS
Third passage FLS (10000 cells/well) were cultured in
DMEM complete medium with or without recombinant IL-
17 (10 ng/ml, ebiosciences), and/or IL-17RA monoclonal
antibody (20 ng/ml, anti-human IL-17RA mAb, M202,
Amgen,) or TNF-a (10 ng/ml) (eBiosciences, San Diego,
CA) in 96-well plates for 5 days at 37C in a humidified
incubator with 5% CO2. Then the supernatants were col-
lected and stored at -20C for ELISA assay to determine
the levels of IL-6, IL-8, and MMP3. ELISA kits were
obtained from RayBiotech Inc., Norcross, GA. The mini-
mum detection limit was 0.3 ng/ml for MMP3, 1 pg/ml for
IL-8 and 6 pg/ml for IL-6.
Quantitative immunoassay of IL-17A (ELISA)
in synovial fluid of psoriatic arthritis, rheumatoid
arthritis, and osteoarthritis patients
Synovial fluid was collected from the knee joints of
patients with PsA (n = 20), RA (n = 20), and OA
(n = 20). All patients had active arthritis. The patients
were on NSAID or Tylenol; no patient was taking corti-
costeroid or biologics. Seven patients with RA were taking
hydroxychloroquine; five patients with PsA and six patients
with RA were on methotrexate (\10 mg/wk). The synovial
fluid was immediately centrifuged at 4009g for 20 min at
4C to remove cells and debris. Supernatant were carefully
removed and stored at -20C. IL-17A concentration was
measured by ELISA using RayBio Human IL-17 ELISA
Kit Protocol, RayBiotech, Norcross GA. For comparison,
paired serum samples of the patients as well as serum from
ten healthy subjects were used as controls. Sensitivity for
IL-17 detection by this kit is 10 pg/ml.
Identification and phenotypic characterization
of the Th17 cells in psoriatic arthritis
Blood and synovial fluid from PsA (n = 12), RA (n = 8),
and OA (n = 12) patients were studied. SFMC and PBMC
were isolated by Ficoll-hypaque gradient centrifugation.
Two million cells per well were activated by culturing for
72 h in a CD3/CD28 (5 lg/ml each) coated 24-well
plate. SFMC from four PsA subjects were also stimu-
lated for 24 h with 1 lg/ml of phorbol myristate acetate
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(Sigma-Aldrich) and 0.25 lg/ml of ionomycin (Sigma-
Aldrich). Monensin was added 6 h prior to harvesting the
cells to block the secretion of intracellular cytokines from
the cells. Then cells were washed and stained with Live-
DeadTM marker (Molecular Probe Inc., Carlsbad, CA),
surface markers of T cells (anti-CD3, CD4, CD8, CD11a,
CD45RA antibodies) and intracellular cytokines (IL-17A,
IFN-c, and IL-4 antibodies) as per our standardized pro-
tocol. In brief, to study T cell surface markers, cells were
incubated with respective fluorochrome conjugated anti-
bodies (BD-Pharmingen, San Diego, CA) for 30 min,
washed twice and resuspended in PBS containing 2% FBS.
Next, the cell suspensions were treated with 250 ll of
cytofix/cytoperm reagent (BD-Pharmingen, San Diego,
CA); cells were then washed with lysis buffer and resus-
pended in lysis buffer containing 2% FBS and kept in ice.
Subsequently, for intracellular staining, fluorochrome
conjugated IL-17A, IFN-c, and IL-4 antibodies (eBio-
sciences, San Diego, CA) were added to lysis buffer and
incubated in ice for 30 min. Finally, cells were washed
twice and resuspended in PBS for FACS analyses. The
controls used were unstained cells and cells stained with
irrelevant primary mouse or rabbit antibodies. Unstained
cells were used to determine autofluoresence. Cells were
analyzed in FACSAria (Becton–Dickinson, San Jose, CA).
At least 500,000 events were collected in DiVa electronic
system. Data were analyzed using FlowJo software (Tree-
star Inc., Ashland, Oregon).
Immunohistochemical staining
Cryosections of 6 lm thickness were prepared from
synovial tissues and skin tissues on Superfrost Plus slides
(VWR Scientific Products, West Chester, PA, USA). Sec-
tions were air-dried and fixed in cold acetone for 5 min.
Serial sections were stained for CD3 and IL-17A. Sections
were washed in PBS 0.1% solution, then incubated for 20 h
at 4C with monoclonal antibodies for IL-17A (eBio-
sciences) and CD3 (Boehringer Mannheim, Indianapolis,
IN). Tissues were washed again with PBS and immunop-
eroxidase staining was performed as per our standardized
protocol [24, 25]. The controls were sections stained by the
same protocol except the primary antibody and sections
stained with isotype antibody. In each section, the entire
tissue was scanned for the presence of positive staining
within the epidermis and dermis. Sections were indepen-
dently examined by two investigators.
Only cells in which staining could be identified without
doubt was considered to be positively stained; this was
determined independently by two investigators. The sur-
face area of the epidermis or dermis was measured with
the help of a reticule/grid (10 9 10 mm with 1 mm2
boxes; Microscoptics, Inc., Milford, MI) placed in the
microscope’s eyepiece. The number of cells positive for a
specific molecule per square mm of epidermis or dermis
was calculated by dividing the total number of positive
cells by the surface area [24, 25].
Statistical analyses
For analyses of FACS data, calculations of absolute cell
numbers and comparisons of means/medians of each phe-
notype under different experimental conditions were per-
formed using the FlowJo software (TreeStar Inc., Ashland,
OR). Statistical analyses were performed with the JMP
statistical software package (SAS Institute, Cary, NC). Cell
proliferation data were analyzed by ANOVA. For histo-
logical studies, ELISA data and Flow cytometry data mean
levels or numbers of each outcome in the study group was
compared to the control group via a two-sided t test. Non-
parametric test (Mann–Whitney U-Test) was used if there
was non-normality in data. A P \ 0.05 was considered
statistically significant.
Results
IL-17RA expression in fibroblast like synoviocytes
of patient with PsA
IL-17RA expression in FLS obtained from RA and PsA
patients and from non-inflammatory conditions like OA
and meniscal tear was detected and compared by FACS
studies (Fig. 1). The expression of IL-17RA in these cells
was further confirmed with western blot assays (Fig. 2). IL-
17R expression was found to be significantly higher in RA
(15.7% ± 4.9) and PsA (4.5% ± 0.9) FLS in comparison
to OA FLS (1.14 ± 0.9%) and FLS obtained from non-
arthritic meniscal tear patients (0.81% ± 0.36) at P B 0.05
(Fig. 1). Analysis of the IL-17RA protein expression in
these cells was determined by western blotting assay and
confirmed the flow data (Fig. 2). The relative intensities
(RI) of IL-17RA expression in RA-FLS, PsA-FLS, OA-
FLS, and meniscal tear-FLS were 2.5, 2.4, 1.3, and 1.4,
respectively.
IL-17 levels in the synovial fluid of PsA and RA
are elevated
IL-17A was detected in the synovial fluid of patients with
RA, PsA, and OA. The IL-17A level was highest in the
PsA group (297.5 pg/ml ± 72 [mean ± SD]). In the RA
group, the level of IL-17A was 228 pg/ml ± 58, whereas
in OA patients the level of IL-17A was 56 pg/ml ± 14. No
significant correlation was observed between the synovial
fluid IL-17A level and patients’ treatment regiment or
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disease severity. IL-17A levels of synovial fluid in PsA and
RA were significantly higher compared to OA (\0.01,
Student t test). The IL-17A level in the sera of RA and PsA
was 16-25 pg/ml; 1L-17A was not detectable in OA and
healthy control sera.
Synovial fluid of psoriatic arthritis is enriched with
IL-17A producing CD4? memory T cells
The high IL-17A levels in the synovial fluid of patients with
PsA spurred us to explore the source of IL-17A. IL-17A–
producing T cells were identified in both CD3/CD28 anti-
body and PMA/Ionomycin activated mononuclear cell
populations derived from peripheral blood and synovial fluid
of the study subjects (Fig. 3). Here we describe the results of
CD3/CD28 antibody activated mononuclear cells because of
its physiological significance. In the PBMC of PsA, RA, OA,
and healthy controls and in the SFMC of OA the percentage
of IL-17A? CD4? T cells were\1% (Table 1). Significant
enrichment of IL-17A–producing T cells (7.9% ± 2.8) was
observed within the synovial fluid as compared to the
peripheral blood of the PsA patients (Fig. 3, Table 1). The
majority of IL-17A? T cells were CD4? (Fig. 3). The fre-
quency of Th17 cells were increased by tenfold in synovial
fluid of PsA patients compared to OA patients (P \ .001,
Table 1). The degree of enrichment did not vary with the
severity of the psoriatic arthritis. Further, the majority of
these CD4? IL-17A? were CD4RO?CD45RA-CD11a?.
These results suggest that at the site of inflammation in PsA,
the effector memory T cells are enriched with IL-17A
expressing T cells along with upregulation of CD11a, a key
molecule for the homing of T cells. Without in vitro stimu-
lation, IL-17A positive staining for IL-17? mononuclear
cells was extremely low. There were \0.1% IL-17A? T
cells in unstimulated PBMC and \0.4 percent IL17A? T
cells in unstimulated synovial fluid cells of psoriatic arthritis
patients. The enrichment of CD4? IL-17A? T cells was
observed in the SF of RA as well (Table 1).
(i) (ii)
(iii) (iv)
Fig. 1 IL-17 receptor A
expression on FLS i 2D FACS
plot showing Isotype control for
IL-17RA along with live dead
stain PI propidium iodide.
ii IL-17RA expression on FLS
from PsA. iii Overlay plot
of IL-17RA expression on FLS
along with isotype control. iv
Histogram showing frequency
of IL-17RA positive cells in
FLS obtained from RA
rheumatoid arthritis, PsA
psoriatic arthritis, MT meniscal
tear, and OA osteoarthritis
Fig. 2 Western blot analysis of IL-17RA a Expression of IL-17RA
on FLS obtained from inflammatory and non inflammatory arthritis.
b Histogram showing relative intensity of IL-17RA expression in FLS
obtained from obtained from RA rheumatoid arthritis, PsA psoriatic
arthritis, MT meniscal tear, and OA osteoarthritis
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Skin and synovial tissue of psoriatic disease
are enriched with Th17
Serial sections from psoriatic arthritis synovial tissue
(Fig. 4a, b) and psoriatic plaque (Fig. 5a, b) demonstrated
that the distribution of IL-17A? T cells is similar to that of
the CD3? T cells, suggesting that IL-17A? cells are T
lymphocytes. Further, Fig. 5b clearly shows that IL-17A?
cells are restricted to the dermis and predominantly local-
ized in the papillary/upper dermis. The numbers of Th17
cells per square millimeter of dermis were significantly
higher in psoriatic dermis (83 ± 20) compared to non-le-
sional psoriatic skin (7 ± 5) (P \ 0.01). The number of
IL-17A? infiltrating T cells per square millimeter was
significantly higher within the psoriatic arthritis synovial
tissue (88 ± 22) compared to synovial tissues of OA
Fig. 3 Synovial fluid of psoriatic arthritis is enriched with IL-17
producing T cells—representative dot plots (n = 12) of IL-17? T
cells. a CD3/CD28 antibody activated synovial fluid mononuclear
cells from a psoriatic arthritis patient were examined for IL-17A
expression by multiparameter FACS analyses. This figure shows that
IL-17A expression is restricted to the CD4? lymphocytes within the
live gated CD3? T cells. Compared to 0.45% IL-17A? cells in the
CD8? T cells there are 5.9% IL-17A? cells in the CD4? T cells.
b Compared to CD3/CD28 antibody activation relatively more IL-
17A? T cells could be identified with PMA/Ionomycin activation. In
gated live CD3? T cells derived from synovial fluid mononuclear
cells (SFMC) from a psoriatic arthritis (PsA) patient it is clearly
demonstrated that IL-17A? expression is restricted to CD3? CD8-
T cells. c This dot plot represents that IL-17A? T cells reside within
the memory cell pool. In gated live CD4? T cells [98% of the IL-
17? cells are CD45? (memory phenotype). PBMC peripheral blood
mononuclear cells, SFMC synovial fluid mononuclear cells
Table 1 Enrichment of CD4? IL-17? T lymphocytes in the syno-
vial fluid of psoriatic arthritis patients compared to the controls
Study group %CD4?IL-17? T lymphocytes (mean ± SD)
SFMC PBMC
Psoriatic arthritis 7.9 ± 2.8* 0.9 ± 0.6
(n = 12)
Rheumatoid arthritis 8.2 ± 3.1* 1.0 ± 0.6
(n = 8)
Osteoarthritis 0.7 ± 0.3 0.6 ± 0.2
(n = 12)
Healthy volunteers Not done 0.6 ± 0.2
(n = 12)
* P \ .001, Student t test, comparison between psoriatic arthritis and
osteoarthritis; and rheumatoid arthritis and osteoarthritis. SFMC
synovial fluid mononuclear cells, PBMC peripheral blood mononu-
clear cells
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(6 ± 2) patients and patients with meniscal tears (4 ± 2)
(P \ 0.01).
In both psoriatic lesions and synovial tissue (Figs. 4, 5),
the number of CD3? cells exceeds the number of IL-17?
cells. This suggests that only a subpopulation of CD3?
cells are IL-17A producing cells; our FACS studies of
lymphomononumclear cells collected from the synovial
fluid of psoriatic patients substantiates this observation.
IL-17RA in FLS derived from psoriatic arthritis is
functionally active: IL-17 induces marked upregulation
of IL-6, IL-8, and MMP-3 in the FLS derived
from PsA patients
IL-17A is a proinflammatory cytokine and has been reported
to induce IL-6 and IL-8 in FLS. Here the effect of IL-17A on
the expression of IL-6 and IL-8 in FLS derived from PsA
synovial tissue and compared with that of FLS derived from
meniscal tear patients without any underlying inflammatory
arthritis. IL-17A treated FLS of PSA produced a signifi-
cantly higher amount of IL-6 and IL-8 compared to the same
FLS without IL-17A treatment (Fig. 6). On the contrary, IL-
17A did not induce significant upregulation of IL-6 and IL-8
in the FLS of meniscal tear patients (Fig. 6). Data on the
regulatory role of IL-17A of MMP-3 is sparse. Results of this
study clearly demonstrate that FLS from PsA treated with
IL-17A produce significantly higher amounts of MMP-3
(Fig. 6). TNF-a also significantly increased the production
of IL-6, IL-8, and MMP-3 (Fig. 6). To further elucidate the
functional significance of the IL-17RA in PsA, we investi-
gated whether blocking the IL-17RA with a monoclonal
antibody that can inhibit IL-17A, IL-17F, IL-17A/F, and IL-
25 cytokine signaling would impact IL-6, IL-8, and MMP-3
production. Results in Fig. 6 clearly demonstrate that an
IL-17RA antibody (M202) effectively reduced secretion of
IL-6, IL-8, and MMP-3. These findings substantiate that
Fig. 4 Synovial tissue of psoriatic arthritis is enriched with IL-
17A? T cells. Serial sections of synovial tissue from psoriatic
arthritis stained with CD3 antibody (a) and IL-17A antibody
(b) demonstrating overlapping of CD3? and IL-17A? lymphocytes.
There are more numbers of CD3? lymphocytes suggesting that a
subpopulation of CD3? cells expresses IL-17A
Fig. 5 Infiltrates in papillary dermis in a psoriatic plaque demon-
strates IL-17A? cells. Serial sections from a psoriasis plaque stained
with CD3 antibody (a) and IL-17A antibody (b). CD3? cells (a) are
present in both epidermis and dermis whereas Th17 cells (b) can be
seen only in upper and deeper dermis
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IL-17RA is functionally effective in cells from psoriatic
arthritis patients.
Discussion
The regulatory role of IL-17 and its receptor system have
provided a new dimension in understanding autoimmune
disease processes. A series of studies have reported evi-
dence for the role of IL-17 in various autoimmune diseases,
including psoriatic disease and rheumatoid arthritis. So far,
no reports are available on IL-17RA in psoriatic arthritis;
functional studies of the IL-17R in other human autoim-
mune diseases are very limited [26–28]. Here we report the
functional significance of IL-17RA in psoriatic arthritis and
give a detailed analysis of IL-17—producing T cells in
PsA.
IL-17RA expression was evaluated in the FLS of
patients with PsA and RA and compared with IL-17RA
expression in FLS of non inflammatory arthritis patients. In
western blot studies, the expression level of IL-17RA in
FLS of PsA patients (mean ± SD) was significantly higher
compared with FLS of OA (mean ± SD) patients and FLS
from patients with meniscectomies (mean ± SD). RI of
IL-17RA in PsA-FLS, OA-FLS, and meniscal tear—FLS
were 2.4, 1.3, and 1.4, respectively. However, IL-17RA
expression was found to be highest in FLS derived from
RA patients (Fig. 2). Increased levels of IL-17RA expres-
sion was further confirmed by flowcytometry studies.
Similar trends of IL-17R expression was observed by
FACS analyses on FLS obtained from RA, PsA, OA, and
meniscal tear patients (Fig. 1). In the synovial fluid of
inflammatory arthritis, such as in RA and PsA, the ligand
for IL-17R (IL-17) is markedly elevated. As the IL-17
receptor (IL-17RA) is expressed ubiquitously, it is expec-
ted that IL-17 and its receptor system (IL-17RA) are
functionally effective in RA and PsA. So there is no tele-
ological requirement for increased expression of IL-17R.
Other studies have also reported a higher expression of IL-
17R in the FLS of RA compared to FLS of OA origin [27].
In this study, by various methods of investigation, an
enrichment of IL-17? T cells (Th17) was observed in the
skin, synovial tissue, and synovial fluid of patients with
psoriasis and psoriatic arthritis. It has been proposed that
IL-17 plays a critical role in the pathogenesis of psoriasis
[29–32]. IL-17 mRNA has been reported in psoriatic
lesions; in a murine model of skin disease, IL-17 induces
autocrine IL-22 production which in turn induces psoria-
siform lesions [30–32]. Th17 cells have been identified
from the dermal extracts of psoriatic lesions [15]. Immu-
nohistochemical staining of psoriasis lesions in serial sec-
tions substantiates that IL-17A? T (Th17) cells are mostly
localized in the dermis (Fig. 5). In psoriasis, CD4? T cells
are known to be localized in the dermis and CD8? T cells
are mainly localized in the epidermis. The Th17 cells are
predominantly a subpopulation of CD4? T cells (Fig. 3),
so the observed localization of Th17 cells in the dermis is
consistent with the characteristic distribution of CD4? T
cells in psoriasis.
IL-17A levels in synovial fluid from PsA and RA
patients were significantly higher compared to OA patients
(P \ 0.01, Student t test). Other groups have also identified
IL-17A in the SF of PsA patients [18, 33, 34]. To obtain a
better insight about the role of IL-17A in PsA, Th17 cells
were also studied in the synovial tissue and in mononuclear
cells derived from SF (Figs. 3, 4). The IL-17A? T cells
were largely CD4? and were CD45R? CD45RA-; this is
consistent with earlier observations that IL-17A? T cells
reside within the memory pool [2, 5]. IL-17A? T cells
were present at significantly higher numbers in the synovial
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Fig. 6 Regulatory role of IL-17A and its receptor IL-17RA, on
production of IL-6, IL-8, and MMP-3 by fibroblast-like synoviocytes
(FLS) derived from PsA (n = 3) and meniscal tear individuals/normal
subjects (n = 3). Third passage FLS (5000 cells/200 ll DMEM
complete medium) were cultured without/with recombinant IL-17
(10 ng/ml) or TNF-a (10 ng/ml). IL-17A treated FLS of psoriatic
arthritis (PsA) patients produced significantly higher amount of IL-6
(a), IL-8 (b), and MMP-3 (c) compared to the same FLS without IL-
17A treatment or FLS from the subjects with meniscal tear. FLS
cultured with TNF-a served as positive controls. Induction of IL-6,
IL-8, and MMP-3 by IL-17A could be significantly inhibited when
FLS were culture together with IL-17A and IL-17RA antibody
(20 ng/ml). This suggests that blocking of the IL-17RA with a
monoclonal antibody can inhibit the IL-17A-induced production of
IL-6, IL-8, and MMP-3 production
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fluid than in either the paired blood samples from PsA
patients or the blood of OA patients and the healthy con-
trols. By the immunohistochemistry study, we have also
shown that PsA synovial tissues are enriched with
IL-17A? T cells (Fig. 4).
In a recent study, Jandus et al. [35] sorted circulating
CD4? T cells from 20 seronegative spondylarthritic
patients, including ten patients with PsA, and cloned these
cells in the presence of low dose IL-2. A significant pro-
portion of the clones from these patients were shown to
produce detectable amounts of IL-17 upon stimulation with
CD3 and CD28 antibodies. The cloned CD4? T cell from
blood is not biologically the same as the functional T cell at
the disease site. In that respect, results of this study are
more meaningful. Here, freshly isolated effector T lym-
phocytes were studied from the synovial fluid in the dis-
eased joints and a significant enrichment of Th17 cells was
observed in patients with clinically active PsA. In our study
population, all patients had clinically active psoriatic
arthritis. However, we did not notice any correlation
between disease severity and levels of IL-17 or numbers of
Th17 cells in the synovial fluid. In a report by Fiocco et al.,
authors have noticed that following treatment with intra-
articular injection of Etanercept in psoriatic arthritis, there
was no significant reduction of synovial fluid IL-17 levels
compared to the pretreatment levels of IL-17. Although
there was a statistically significant reduction in posttreat-
ment IL-1b, IL-1Ra, IL-6, and IL-22 levels with respect to
basal values. In a recent study, Leipe et al. [34] have
reported that in DMARD naı¨ve patients, the frequencies of
Th17 cells and levels of interleukin-17 correlated with
systemic disease activity in PsA patients (mean disease
duration \3 months). Our patient population and patients
of Fiocco et al. were not of early onset and were not
DMARD naı¨ve. Thus, disease pattern, treatment regimen,
and ethnicity of patients were different in these studies and
outcomes of these results may not be comparable.
Several reports suggest that IL-17 can influence bone
and cartilage destruction in inflammatory arthritis [36, 37].
In animal arthritis models, disease severity is less in IL-17-
deficient mice [38]. Treatment with an anti-IL-17 antibody
is therapeutically effective and reduces IL-6 levels and
bone erosion [10, 39]. IL-17 receptor deficiency results in
impaired synovial expression of IL-1 and MMP-3, MMP-9,
and MMP-13 and prevents cartilage destruction during
chronic reactivated streptococcal cell wall-induced arthritis
[40]. Other investigators have reported that IL-17A
upregulates the expression of IL-6, IL-8, MMP-1, and
MMP-3 in cultured FLS from RA and JIA [6, 41].
Recently, these observations have been substantiated with
co-cultures of RA-FLS and Th17 cells; further it was
noticed that IL-17A neutralization could suppress these
actions of the Th17 cells [42].
To understand the role of IL-17/IL-17RA in the joint
pathology of PsA, the effect of IL-17 in PsA-FLS was
determined in respect to production of proinflammatory
cytokines and endopeptidase. Results of this study suggest
that FLS from PsA patients are tuned to a robust response
following stimulation with IL-17A (Fig. 6). There was a
marked upregulation of IL-6, IL-8, and MMP-3 upon
exposure to IL-17A in cultured FLS from all three PsA
patients (Fig. 6). These results indicate that IL-17A can
enhance inflammation and cellular infiltration in the syn-
ovium; IL-17A can also mediate bone and cartilage dam-
age in PsA. The functional significance of IL-17RA was
further substantiated by demonstrating that the use of a
monoclonal antibody against IL-17RA inhibits the
expression of proinflammatory cytokines and metallopro-
teinases. Thus, IL-17RA blocking might be a potential
target for developing new therapeutic approaches for pso-
riatic arthritis.
It is important to understand the role of Th17 cells in the
initiation and maintenance of the psoriatic disease process.
Studies have demonstrated that the p40 subunit and the IL-
23 specific p19 subunit, not the IL-12-specific p35 subunit,
are highly expressed in monocyte and DC in psoriatic skin
lesions [43–45]. Recent reports suggest that targeting the
shared IL-12/IL-23 p40 subunit is an effective treatment
for psoriasis [46, 47]. These observations suggest that IL-
23 produced by the activated DC is likely an upstream
event in triggering the inflammatory and proliferative
cascades of psoriasis [42–47]. IL-23 activates the Th17
cells to produce Th17 cytokines such as IL-17 and IL-22.
Th17 cell derived cytokines will have more downstream
effects such as epidermal thickening, angiogenesis, and cell
trafficking [5, 7, 25–27, 47–49].
To summarize, the results of this study suggest that
synovial tissue in psoriatic arthritis is enriched with IL-17
and its most well-recognized receptor, IL-17RA. It was
noticed that IL-17RA is functionally active in psoriatic
arthritis; it regulates the expression of cytokines and matrix
metalloproteinase, which are essential for the disease pro-
cess of psoriatic disease (Fig. 6). Earlier reports suggest
that IL-17 also promotes bone erosion through the up-
regulation of RANKL [9, 39], a key regulator of osteo-
clastogenesis. RANKL has been demonstrated in high
levels in psoriatic arthritis [50]. Thus, the downstream
effects of IL-17 are likely to influence all the major com-
ponents of the pathologic events of psoriatic disease in skin
and joint tissues. The cellular and molecular studies
described here support the hypothesis that IL-17A/IL-
17RA contribute to connective tissue and epithelial tissue
remodeling in psoriatic disease. Further, the results of this
study support that blocking of IL-17RA with a monoclonal
antibody could be a therapeutic option for psoriatic
arthritis.
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